- Microelectrode arrays (MEAs) are essential tools in neurophysiological research, enabling the recording and stimulation of neuronal activity in vitro. They play a crucial role in drug discovery, neurotoxicity screening, and disease modelling for conditions such as epilepsy, Parkinson’s, and Alzheimer’s
- The demand for MEAs is significantly driven by the rising prevalence of neurological disorders, increased investment in neuroscience research, and the growing adoption of high-throughput screening techniques. Pharmaceutical and biotech companies are increasingly utilizing MEAs for drug development and toxicity assessment
- The North America region stands out as one of the dominant regions for the MEA market, driven by its strong research infrastructure, presence of key market players, and government funding in neurological and biomedical research
- For instance, the U.S. sees continuous advancements in neurotechnology and brain research initiatives, with academic institutions and pharmaceutical firms heavily investing in MEA-based studies for drug screening and disease modeling
- Globally, microelectrode arrays rank among the most critical technologies for in vitro electrophysiology studies, following patch-clamp techniques, and play a pivotal role in advancing precision medicine and neural interface research
